#veterinarydiagnostics

The global veterinary urinalysis market is witnessing strong growth as pet owners, veterinarians, and livestock managers increasingly focus on preventive healthcare and early disease detection. Urinalysis has become a crucial diagnostic tool for identifying kidney disorders, urinary tract infections, diabetes, liver diseases, and other systemic conditions in animals.

The market was valued at USD 1.10 billion in 2025 and is projected to increase from USD 1.17 billion in 2026 to approximately USD 2.05 billion by 2035, growing at a CAGR of 6.40% from 2026 to 2035. Rising pet ownership, expanding veterinary care infrastructure, and growing demand for rapid and accurate diagnostic solutions are among the major factors driving market growth.

Why is the Veterinary Urinalysis Market Expanding So Rapidly?

The growing importance of preventive healthcare for animals is significantly increasing the use of veterinary urinalysis. Pet owners are increasingly opting for routine wellness checkups, where urinalysis is commonly used to identify early signs of disease before symptoms become severe.

In addition, the increasing number of companion animals worldwide is creating greater demand for diagnostic services. Veterinary clinics and hospitals are also investing in more advanced urinalysis analyzers and portable testing systems to improve efficiency and reduce turnaround times. Livestock producers are adopting urinalysis as part of herd health management strategies to improve productivity and prevent disease outbreaks.

Quick Insights: Key Market Highlights

North America dominated the veterinary urinalysis market with a 40% share in 2025.

Asia Pacific is expected to grow at the fastest CAGR of 8.5% between 2026 and 2035.

By product type, analyzers held the largest market share of 45% in 2025.

By animal type, pets accounted for 60% of the market in 2025.

Kidney disease was the leading application segment, contributing 40% of market share in 2025.

Veterinary clinics dominated the market with a 55% share in 2025.

How is AI Transforming Veterinary Urinalysis?

Artificial intelligence is beginning to reshape veterinary diagnostics by making urinalysis faster, more accurate, and more efficient. AI-enabled analyzers can process urine samples more precisely, detect abnormalities, and reduce the risk of manual errors.

Connected diagnostic systems are also helping veterinary professionals make faster clinical decisions by integrating urinalysis with broader patient records and laboratory platforms. These technologies improve disease detection, support early intervention, and streamline workflow in veterinary clinics and hospitals. The U.S. market, in particular, is seeing strong adoption of AI-enabled urinalysis analyzers and automated systems.

What Are the Key Growth Drivers?

Several factors are contributing to the growth of the veterinary urinalysis market:

Increasing pet ownership worldwide

Rising demand for preventive animal healthcare

Growing prevalence of kidney disease, urinary tract infections, and diabetes in pets

Expansion of veterinary clinic chains and diagnostic laboratories

Higher spending on companion animal health

Technological advancements in analyzers, test strips, and reagent kits

Increasing adoption of portable and point-of-care testing devices

What Trends and Opportunities Are Shaping the Market?

Is Point-of-Care Testing Becoming a Major Trend?

Yes. Veterinary professionals are increasingly adopting portable urinalysis devices that can provide immediate results within clinics and farms. This trend is helping veterinarians diagnose diseases faster and begin treatment more quickly.

Are Pet Insurance Plans Increasing Diagnostic Spending?

Absolutely. As pet insurance penetration increases, owners are more willing to spend on advanced diagnostic tests, including urinalysis. This is helping drive routine testing and preventive care for companion animals.

Are Multi-Test Platforms Improving Veterinary Diagnostics?

Yes. Diagnostic companies are increasingly integrating urinalysis with other biochemical, immunological, and molecular testing systems to create comprehensive animal diagnostic platforms. This allows veterinarians to assess multiple conditions through a single device.

Regional Analysis: Which Regions Are Leading the Market?

North America dominated the veterinary urinalysis market in 2025 with a 40% share due to high pet ownership rates, strong spending on animal healthcare, and widespread adoption of advanced diagnostic technologies. Approximately 66% of households in the U.S. own pets, contributing to frequent veterinary visits and increased use of diagnostic testing.

Europe represented the second-largest regional market with a 25% share in 2025, supported by growing awareness of animal wellness and a well-established veterinary care ecosystem. Asia Pacific is projected to grow at the fastest pace due to rising pet adoption, expanding livestock management practices, and increasing investments in veterinary healthcare infrastructure.

Segmental Analysis: Which Segments Dominate the Market?

By Product Type

The analyzers segment led the market with a 45% share in 2025 because of its ability to improve diagnostic accuracy and reduce manual errors. Reagents held a 35% share and are expected to continue growing due to their importance in automated testing systems. Test strips are projected to grow at the fastest CAGR of 7% because they are affordable, easy to use, and provide rapid results.

By Animal Type

Pets dominated the market with a 60% share in 2025, driven by the rising number of companion animals and increased spending on pet wellness. Livestock accounted for 35% of the market and is expected to grow steadily due to the increasing need for herd health management and disease monitoring.

By Application

Kidney disease remained the leading application area with a 40% share in 2025 because urinalysis is widely used for early detection of renal conditions. Urinary tract infections held a 25% share, while diabetes mellitus is expected to grow at the fastest CAGR of 8% due to increasing obesity rates among pets.

By End-Use

Veterinary clinics led the market with a 55% share in 2025, driven by their role in routine wellness exams and preventive care. Animal hospitals followed with a 25% share because they handle more specialized and complex cases that require detailed diagnostic testing.

Case Study: How Portable Urinalysis is Improving Veterinary Care

Many veterinary clinics are now using portable urinalysis devices during routine wellness visits. These tools allow veterinarians to diagnose kidney disease, UTIs, and diabetes in real time, improving the speed of care and helping pet owners make faster treatment decisions.

Americans have always been a nation of pet lovers, but the depth and seriousness with which US households now approach pet healthcare has reached a level that is reshaping entire industry segments. Pets are no longer simply animals kept for companionship. For a growing majority of American households, they are family members whose health and longevity command the same level of attention, investment, and medical sophistication as any other loved one.

The U.S. companion animal diagnostics market was valued at USD 2.88 billion in 2023 and is projected to reach USD 4.28 billion by 2029, growing at a compound annual growth rate of 6.81%. This growth is being driven by a convergence of demographic, behavioral, and technological factors that are deepening both the demand for veterinary diagnostic services and the sophistication of the tools available to deliver them.

Click : U.S. Companion Animal Diagnostics Market - Focused Insights 2024-2029

The Scale of Pet Ownership in America

The numbers behind American pet ownership put the market's growth trajectory in immediate context. Over 70% of U.S. households, equivalent to approximately 91 million homes, currently own at least one pet, a figure that represents an all-time high according to the American Pet Products Association's national survey data. Pet owners in the US spent USD 66 billion on their pets in the most recent measured year, a figure that spans food, veterinary care, grooming, insurance, and health products.

Post-pandemic data reveals a particularly striking dimension of this trend. Surveys conducted in 2022 found that 58% of dog owners and 54% of cat owners strongly prioritize seeking products and services that actively improve their pets' health and wellness rather than simply addressing illness after it occurs. This shift from reactive to proactive pet healthcare is a direct driver of diagnostic demand, because early detection, preventive screening, and ongoing health monitoring all require diagnostic tools and tests that generate consistent revenue for manufacturers, laboratories, and veterinary practices.

Disease Burden Translating Into Diagnostic Necessity

The growth in companion animal populations is inevitably accompanied by a corresponding increase in the incidence and range of diseases requiring diagnosis and treatment. Dogs are particularly susceptible to a wide variety of conditions including allergies, infections, diabetes, dental disorders, obesity, heartworm, and parvovirus, conditions that range from acutely life-threatening to chronic and requiring ongoing management. The veterinary care costs associated with dogs tend to be higher than those for cats, reflecting both the greater disease burden and the larger size and therefore more resource-intensive treatment requirements of canine patients.

As of 2023, approximately 90 million dogs live in the United States, each representing a potential diagnostics customer across their lifespan. The companion animal diagnostics market is essentially a market built on the intersection of affection and obligation: pet owners who care deeply about their animals' wellbeing and who have the financial means, through out-of-pocket spending or increasingly through pet insurance, to invest in the diagnostic procedures that enable accurate diagnosis and effective treatment.

Consumables as the Revenue Backbone

The product landscape of the companion animal diagnostics market reflects the broad scope of diagnostic activity that the market encompasses. Consumables held over 66% of total market share in 2023, a dominance that reflects the recurring, high-volume nature of test kits, substrates, enzymes, electrolyte reagents, and specific protein assays that underpin diagnostic laboratory operations. Each diagnostic test performed generates consumable demand, creating a revenue stream that scales directly with the volume of diagnostic activity in the market.

Diagnostic analyzers and imaging equipment represent the higher-capital, lower-frequency purchasing segment, while software increasingly ties these components into integrated diagnostic workflows that improve efficiency, accuracy, and record-keeping across veterinary practices of all sizes. The combination of recurring consumable revenue with periodic capital equipment refresh and growing software subscription revenue creates a commercially attractive and relatively stable market structure for vendors positioned across multiple product categories.

Pet Insurance Amplifying Willingness to Invest in Diagnostics

One of the most commercially significant structural changes in the U.S. companion animal healthcare market is the growing adoption of pet insurance. Insurance coverage directly reduces the out-of-pocket cost barrier that previously prevented some pet owners from authorizing the diagnostic procedures that their veterinarians recommended. As more households carry pet insurance, the rate of diagnostic test authorization per veterinary visit increases, generating incremental revenue for the diagnostics market that is directly attributable to insurance penetration growth. This dynamic creates a virtuous cycle in which greater insurance coverage supports higher diagnostic utilization, which in turn generates better health outcomes that reinforce the perceived value of insurance, encouraging further adoption.

The global veterinary oncology diagnostics market is expected to reach USD 3.45 billion by 2030, registering a CAGR of 8.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, shifting focus on preventative animal healthcare, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

Additionally, the development of advanced veterinary cancer diagnostic tests, such as the world's first and only at-home cancer screening test by Oncotect, is creating lucrative opportunities in the veterinary oncology diagnostics market. This innovative canine cancer screening test enables early detection, improving treatment outcomes and offering peace of mind to pet owners. Oncotect, which detects the four most prevalent types of canine cancer, can be used at home or in-clinic, making it user-friendly and accessible. The rise in at-home testing solutions, coupled with clinical data supporting its accuracy, is expanding the market for veterinary oncology diagnostics, particularly by increasing accessibility for pet parents.

Furthermore, the increasing prevalence of cancer in pets is significantly driving the growth of the veterinary oncology diagnostics market. As per The Veterinary Cancer Society, Cancer is the top reason of death in 47% of canines, particularly those over 10 years old, and in 32% of felines. Around 1 in 4 dogs will experience abnormal tissue growth, or neoplasia, during their lifetime. With nearly 100 types of cancer affecting pets, a diagnosis can be overwhelming, yet advances in veterinary care have improved treatment success rates for both dogs and cats. Similarly, cancer is the leading cause of death in cats and dogs, affecting one in four dogs and one in five cats in Australia, according to a May 2024 study by the Australian Research Data Commons (ARDC). In the U.S., about 6 million pet dogs are expected to be diagnosed with cancer in 2024, creating a unique opportunity to improve cancer diagnosis for both pets and humans, as reported by The Cancer Letter Inc. Additionally, the American Veterinary Association states that one in four dogs will develop neoplasia at some point, and about half of dogs over the age of 10 will develop cancer.

For More Details or Sample Copy please visit link @: Veterinary Oncology Diagnostics Market Report

Veterinary Oncology Diagnostics Market Report Highlights

By test type, the biopsy segment dominated the market with a share of 32.08% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.48% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.

In terms of animal type, the canine segment attributed to the largest market share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.

In terms of cancer type, the skin cancers segment accounted for the highest market share in 2024 and is expected to grow at the fastest CAGR of 8.56% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.

By end use, the veterinary hospitals and clinics segment held the highest share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.

By region, North America had the largest share, 53.9%, of the market in 2024 and is anticipated to grow the fastest, at 8.6%, in the coming years.

Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

The global veterinary oncology diagnostics market is expected to reach USD 3.45 billion by 2030, registering a CAGR of 8.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, shifting focus on preventative animal healthcare, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

Additionally, the development of advanced veterinary cancer diagnostic tests, such as the world's first and only at-home cancer screening test by Oncotect, is creating lucrative opportunities in the veterinary oncology diagnostics market. This innovative canine cancer screening test enables early detection, improving treatment outcomes and offering peace of mind to pet owners. Oncotect, which detects the four most prevalent types of canine cancer, can be used at home or in-clinic, making it user-friendly and accessible. The rise in at-home testing solutions, coupled with clinical data supporting its accuracy, is expanding the market for veterinary oncology diagnostics, particularly by increasing accessibility for pet parents.

Furthermore, the increasing prevalence of cancer in pets is significantly driving the growth of the veterinary oncology diagnostics market. As per The Veterinary Cancer Society, Cancer is the top reason of death in 47% of canines, particularly those over 10 years old, and in 32% of felines. Around 1 in 4 dogs will experience abnormal tissue growth, or neoplasia, during their lifetime. With nearly 100 types of cancer affecting pets, a diagnosis can be overwhelming, yet advances in veterinary care have improved treatment success rates for both dogs and cats. Similarly, cancer is the leading cause of death in cats and dogs, affecting one in four dogs and one in five cats in Australia, according to a May 2024 study by the Australian Research Data Commons (ARDC). In the U.S., about 6 million pet dogs are expected to be diagnosed with cancer in 2024, creating a unique opportunity to improve cancer diagnosis for both pets and humans, as reported by The Cancer Letter Inc. Additionally, the American Veterinary Association states that one in four dogs will develop neoplasia at some point, and about half of dogs over the age of 10 will develop cancer.

For More Details or Sample Copy please visit link @: Veterinary Oncology Diagnostics Market Report

Veterinary Oncology Diagnostics Market Report Highlights

By test type, the biopsy segment dominated the market with a share of 32.08% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.48% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.

In terms of animal type, the canine segment attributed to the largest market share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.

In terms of cancer type, the skin cancers segment accounted for the highest market share in 2024 and is expected to grow at the fastest CAGR of 8.56% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.

By end use, the veterinary hospitals and clinics segment held the highest share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.

By region, North America had the largest share, 53.9%, of the market in 2024 and is anticipated to grow the fastest, at 8.6%, in the coming years.

Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

🧬 Exciting Update for Cryptosporidiosis Diagnostics! 🚨

GeneMedi offers high-quality Cryptosporidium parvum antibodies & antigens for diagnosing cryptosporidiosis in animals and humans. 🐾👩‍⚕️

🔍 Why Choose Our Products?

🐄 Targets C. parvum in cats, dogs, cattle, sheep, goats, pigs, poultry, fish, deer, and humans.

🧪 Includes: Recombinant protein & antibodies (Cat No. GMP-VT-P259-Tg000-Ag01, Ab01–Ab04). p23 protein & antibodies (Cat No. GMP-VT-P259-Tg001-Ag01, Ab01–Ab04).

✅ High accuracy for ELISA, LFIA, CLIA, TINIA, and POCT.

🌟 Combat this zoonotic disease causing diarrhea with reliable diagnostics!